CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
0.780
-0.036 (-4.42%)
Feb 21, 2025, 4:00 PM EST - Market closed
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.77, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 639.74% from the current stock price of 0.78.
Analyst Consensus: Buy
* Price targets were last updated on May 28, 2024.
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 22, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 27, 2024 |
Financial Forecast
Revenue This Year
124.04M
from 101.21M
Increased by 22.55%
Revenue Next Year
77.80M
from 124.04M
Decreased by -37.28%
EPS This Year
-0.04
from -0.01
EPS Next Year
-0.47
from -0.04
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 139.7M | 138.6M | 88.9M | |||
Avg | 124.0M | 77.8M | 34.3M | |||
Low | 110.3M | 30.4M | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 38.0% | 11.7% | 14.3% | |||
Avg | 22.6% | -37.3% | -55.8% | |||
Low | 8.9% | -75.5% | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 0.15 | -0.13 | -0.46 | |||
Avg | -0.04 | -0.47 | -0.75 | |||
Low | -0.37 | -0.93 | -0.92 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.